Walleye Trading’s Disc Medicine IRON Stock Holding History

Walleye Trading’s Portfolio IRON Stock Details IRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-490	Closed	-$95K	–	5446
2021 Q2	$95K	Buy	+490	New	+$161K	﹤0.01%	4399

Other funds holding IRON

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Walleye Trading's IRON Position: Q2 2022 in Review

Walleye Trading sold out of Disc Medicine (IRON) in Q2 2022, closing a stake of 343 shares — an estimated $14K sold.

Walleye Trading first reported a position in IRON in Q2 2021 and held it in 4 quarters. The position peaked at $148K in Q2 2021. 50 funds tracked by Wall St. Rank hold IRON as of Q2 2022.

Walleye Trading reported no remaining Disc Medicine position as of Q2 2022 after selling out during the quarter.
Walleye Trading sold 343 Disc Medicine shares in Q2 2022, an estimated $14K.
Walleye Trading first reported a position in Disc Medicine in Q2 2021 and held it in 4 quarters.
Walleye Trading's Disc Medicine position peaked at $148K in Q2 2021.
50 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2022.

Based on Walleye Trading's 13F filing for Q2 2022, filed 8 Aug 2022.